NY-AQARA
23.11.2022 09:01:38 CET | Business Wire | Press release
Aqara, a leading provider of smart home products, introduces its new Cube T1 Pro, which is the updated version of its iconic wireless Cube controller. Built upon the success of its predecessor, the new cube adds HomeKit and Alexa support1, so that it can be used to control a wide range of smart home devices within both ecosystems. Moreover, it adds the new Scene Mode to allow users to use not only actions but also different sides of the cube to activate smart home scenes or devices2. The Cube T1 Pro is now available on Aqara Amazon brand stores in North America (US, Canada) and Europe (France, Germany, Italy, Spain, UK), and via selective Aqara retailers worldwide.
Similar to its predecessor, the Cube T1 Pro recognizes different actions such as push, shake, rotate, flip and tap. A new Scene Mode is added, and when the mode is activated the cube also recognizes different sides, so that users can simply use each side to control various scenes and devices. Dice-like indicators are printed on the sides to help users distinguish one from the others. Moreover, thanks to this new mode the Cube T1 Pro can be used in both HomeKit and Alexa. It’s also expected to support Matter via the Aqara hubs through an OTA update, and the Hub M2 will be the first hub to receive such update.
With all these improvements, the Cube T1 Pro enables a more intuitive way to control a smart home2. For instance, users can activate the Morning Routine by flipping it to Side 1, and trigger the Home Cinema Scene by flipping it to Side 2. Additionally, it’s now possible within the Aqara Home app to control more than one sets of curtains, roller shades or lights by rotating the new cube. For example, flipping it to Side 3 and rotating the cube to adjust the open percentage of the curtains, and flipping it to Side 4 and rotating to dim the Aqara lights3. The versatility of this cube controller allows users to be creative with their smart home setups.
Based on the Zigbee 3.0 protocol which allows faster response, higher reliability, better compatibility and improved energy efficiency, the Cube T1 Pro has a battery life of up to 2 years. It also supports OTA updates, which means that new features and fixes can be added to the new cube after the its initial release.
In celebration of the launch, Aqara now offers a 10% discount for the new cube on its Amazon stores. North American customers will enjoy the offer with the promo code NACUBET1 in the US and Canada, while European customers will enjoy it using the promo code CBT1PROEU in France, Germany, Italy, Spain and the UK. Both codes can be combined with coupon, and will be valid through November 24, 2022.
For more details of the Cube T1 Pro, please visit our website.
- A Zigbee 3.0-based Aqara hub is required. The Cube T1 Pro is recognized as 6 wireless buttons in HomeKit, and as 6 motion sensors in Alexa.
- A Zigbee 3.0-based Aqara hub is required.
- The compatible Aqara lights, Curtain Driver E1 or Roller Shade Driver E1 are required.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221123005015/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom